Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer].

Zhonghua yi xue za zhi - 15 Dec 2015

Zhang Ruixiang, Li Yin, Chen Yawei, Liu Xianben, Wang Zongfei, Sun Haibo, Zheng Yan, Ding Zhidan, Lan Ling, Li Mingzhen, Qin Jianjun, Chen Xiankai

Abstract excerpt

OBJECTIVE: To analyze the correlation between the concentration of plasma cell free DNA (cfDNA) of patients with lung cancer or esophageal cancer and clinical features, and to assess the coincidence rate of the EGFR/KRAS mutations between the cfDNA and tumor tissue DNA. METHODS: A total of 30 cases lung cancer and esophageal cancer (including 15 lung cancer, 15 esophageal cancer) were enrolled in this study. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to ErbB Receptors

Share to Esophageal Neoplasms

Share to Lung Neoplasms

Share to Polymerase Chain Reaction

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 27337801

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer].PMID 27337801Read ↗

[Research Progress of Circulating Tumor DNA in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Differences in the genomic profiles of cell‐free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLCSemantic proximity Read ↗

Clinical relevance of cell-free DNA in gastrointestinal tract malignancySemantic proximity Read ↗

[Research Advancement on EGFR Mutation Detection of Cell-free DNA and Tumor Cell in Peripheral Blood of Patients with Non-small Cell Lung Cancer].Semantic proximity Read ↗

Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.Semantic proximity Read ↗

A Review of Circulating Tumor DNA in the Diagnosis and Monitoring of Esophageal Cancer.Semantic proximity Read ↗

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.Semantic proximity Read ↗

Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancerSemantic proximity Read ↗

Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patientsSemantic proximity Read ↗

Mutation differences in circulating tumor DNAs from non-small cell lung cancer patients between Uygur and Han populations.Semantic proximity Read ↗

Sputum cell-free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR-TKIs.Semantic proximity Read ↗

KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.